par Teixeira, Luis;Rothé, Françoise ;Sotiriou, Christos
Référence European Oncology and Haematology, 12, 1, page (28-29)
Publication Publié, 2016-06
Article révisé par les pairs
Résumé : Significant advances in next-generation sequencing technologies have allowed the identification of genomic alterations in breast cancer. These alterations offer the opportunity to conduct studies with targeted drugs. However, there are still several scientific challenges to be addressed before precision medicine is widely used in the clinic. Nonetheless, different solutions are developed to overcome these obstacles such as the improvement of bioinformatics tools and the use of "liquid biopsy" to assess circulating tumour DNA.